Cortagen

Cortagen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide bioregulator originally derived from brain cortex tissue, marketed as a compound that influences gene expression and helps maintain nervous-system homeostasis. Its main proposed uses are supporting neuroregeneration, improving cerebrovascular function, and regulating inflammatory responses within the central nervous system. Like most peptides, it is sold as a research chemical requiring reconstitution and injection, where purity and storage conditions matter.

The evidence here warrants caution. Cortagen carries a C+ grade, weighted across 14 peer-reviewed studies split evenly between 7 animal and 7 in vitro studies, with 9 supporting findings, 3 mixed, and 2 null. Critically, there are no human RCTs or meta-analyses on file at all. That means every claim about benefits rests on animal models and cell-culture work, with no controlled human data to confirm whether any of it translates to people. Notably, the page itself cites only 2 studies directly, so even the supportive literature is thin.

What the research shows is suggestive rather than conclusive. A microarray study in mice found that Cortagen altered the expression of over 100 genes in cardiac tissue, which the authors read as evidence of systemic bioregulatory activity reaching beyond the brain. A review of cognition-enhancing peptides discussed how compounds like Cortagen may improve synaptic function and support learning and memory by optimizing biological processes in the nervous system. Beyond these, the supporting picture leans on the broader animal and in vitro record rather than on human trials.

Who should be cautious: essentially anyone expecting proven clinical results in humans, because that data does not exist here. The compound is described as having post-traumatic recovery potential for normalizing nerve function after trauma or ischemic events, and it has been shown to affect 110+ genes across various functional categories with activity in cardiac and immune tissues as well as the brain, but these remain preclinical observations.

Community sentiment is almost nonexistent. Across just 2 community reports, 50% were positive and 50% neutral, with general help among the mentioned effects, a sample far too small to support any conclusion. Mention activity has also declined sharply year over year.

On dosing, it is often given as a daily subcutaneous or intramuscular injection for 5-10 consecutive days, typically run in short burst cycles 2-3 times per year rather than continuously, with research protocols using 5-10 mg daily for short-term bioregulation.

Availability is through specialized peptide vendors worldwide, sold specifically for laboratory and research use. It is generally unscheduled but intended for use by licensed professionals in most jurisdictions. The honest summary: an interesting preclinical profile with a notably high reported safety margin, but no human trial evidence, so the enthusiasm around it runs well ahead of what the data can actually back up.